Table 2.

Relationships of ALI with all-cause and cancer mortality in patients with skin cancer from the NHANES 1999–2018 cohort.

ALI	All -cause mortality
	Crude	Model 1	Model 2	Model 3
Skin cancer*	HR, 95%CI	HR, 95%CI	HR, 95%CI	HR, 95%CI
Quantile 1	ref	ref	ref	ref
Quantile 2	0.54(0.38,0.77)	0.80(0.59,1.08)	0.75(0.56,1.01)	0.77(0.57,1.05)
Quantile 3	0.30(0.21,0.43)	0.51(0.37,0.70)	0.48(0.35,0.66)	0.50(0.36,0.69)
Quantile 4	0.31(0.22,0.44)	0.60(0.42,0.84)	0.53(0.37,0.74)	0.54(0.38,0.77)
P for trend	<0.001	<0.001	<0.001	<0.001
	Cancer mortality
	Crude	Model 1	Model 2	Model 3
Skin cancer*	HR, 95%CI	HR, 95%CI	HR, 95%CI	HR, 95%CI
Quantile 1	ref	ref	ref	ref
Quantile 2	0.84(0.46,1.54)	1.16(0.65,2.08)	1.18(0.65, 2.16)	1.20(0.66, 2.18)
Quantile 3	0.28(0.12,0.63)	0.40(0.17,0.94)	0.38(0.16, 0.89)	0.38(0.16, 0.89)
Quantile 4	0.42(0.20,0.91)	0.67(0.31,1.47)	0.64(0.30, 1.38)	0.64(0.30, 1.35)
P for trend	0.005	0.090	0.060	0.049

ALI, advanced lung cancer inflammation index; ref, reference; HR, hazard ratios; CI, confidence interval; CVD, cardiovascular disease; ALT, alanine aminotransferase; LDH, lactic dehydrogenase; Cr, creatinine.

Values are n or weighted HR (95% CI). Model 1: adjusted for age (years), gender (male or female), and race or ethnicity (White, Black, Mexican American, or other). Model 2: model 1+ adjusted for smoke status (never, former, or now), alcohol (never, former, mild, moderate, or heavy), and disease status (yes or no, including a history of hypertension, diabetes mellitus, and CVD). Model 3: model 2+ adjusted for ALT (U/L), LDH(mmol/L), and Cr(umol/L).

* Skin cancer, including melanoma, non-melanoma, and skin (unknown type).